KUWAIT CITY, June 4: The Ministry of Health announced on Wednesday that Kuwait, through its Drug and Medical Products Registration Department under the Drug Control Sector, has officially joined the International Pharmaceutical Regulators (IPR) Program — a significant move toward strengthening its global role in pharmaceutical regulation.

In a press statement, the ministry described the IPR program as a global consortium of leading regulatory authorities dedicated to enhancing international collaboration in the regulation and evaluation of advanced pharmaceutical products, particularly innovative drugs and biological, genetic, and cellular therapies.

Kuwait's membership was formally confirmed during a recent meeting of the program’s administrative committee held in Madrid, Spain. The ministry noted that the accession marks an important milestone in improving the efficiency and effectiveness of the country’s drug control systems, underscoring Kuwait’s commitment to being an active and responsible partner in global health and pharmaceutical development.

The statement further noted that participation in the IPR program allows Kuwait to join specialized international working groups focused on the evaluation of modern pharmaceutical preparations. It also provides access to advanced expertise from leading global regulatory agencies, helping to shape national policies and enhance the performance of Kuwait’s regulatory framework in line with the latest scientific and technological advances in healthcare.

Additionally, membership will support efforts to modernize the country’s procedures for evaluating and registering innovative medicines, while promoting the exchange of technical data and regulatory information within internationally recognized frameworks.